Epidemiology of Adenocarcinoma of the Esophagogastric Junction

Surgical Oncology Clinics of North America

Volumn 15, Issue 4, 2006, Pages 687-696

  Keeney, Scott ^a   Bauer, Thomas L ^b,c  

^a CHRISTIANA CARE HEALTH SYSTEM   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c HELEN F GRAHAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMINOPHYLLINE; ASCORBIC ACID; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA CAROTENE; CALCIUM CHANNEL BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CYCLOOXYGENASE 2 INHIBITOR; GLYCERYL TRINITRATE; NONSTEROID ANTIINFLAMMATORY AGENT;

ALCOHOLISM; BARRETT ESOPHAGUS; CANCER CLASSIFICATION; CANCER EPIDEMIOLOGY; DIET SUPPLEMENTATION; ESOPHAGEAL ADENOCARCINOMA; GASTRITIS; GASTROESOPHAGEAL REFLUX; HELICOBACTER PYLORI; HUMAN; INCIDENCE; INTESTINE METAPLASIA; LOWER ESOPHAGUS SPHINCTER; NUTRITION; OBESITY; REVIEW; SMOKING;

ADENOCARCINOMA; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; HUMANS; UNITED STATES;

EID: 33749337617     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2006.07.014     Document Type: Review

References (52)

1. Parkin D.M., Bray F., Ferlay J., et al. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
2. Blot W.J., Devesa S.S., Kneller R.W., et al. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 265 (1991) 1287-1289
3. Yang P.C., and Davis S. Incidence of cancer of the esophagus in the US by histologic type. Cancer 61 (1988) 612-617
4. Devesa S.S., Blot W.J., and Fraumeni Jr. J.F. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 83 (1998) 2049-2053
5. Botterweck A.A., Schouten L.J., Volovics A., et al. Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol 29 (2000) 645-654
6. Kelley J.R., and Duggan J.M. Gastric cancer epidemiology and risk factors. J Clin Epidemiol 56 (2003) 1-9
7. Jemal A., Thomas A., Murray T., et al. Cancer statistics, 2002. CA Cancer J Clin 52 (2002) 23-47 [erratum appears in CA Cancer J Clin 2002;52(2):119]
8. Pera M., Cameron A.J., Trastek V.F., et al. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 104 (1993) 510-513
9. Parkin D.M., Whelan S.L., Ferlay J., et al. Cancer incidence in five continents, vol. VII (1997), IARC Scientific Publications, No. 143, Lyon (France)
10. Cameron A.J. Epidemiology of Barrett's esophagus and adenocarcinoma. Dis Esophagus 15 (2002) 106-108
11. Zheng T., Mayne S.T., Holford T.R., et al. The time trend and age-period-cohort effects on incidence of adenocarcinoma of the stomach in Connecticut from 1955-1989. Cancer 72 (1993) 330-340
12. Siewert J.R., and Stein H.J. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 85 (1998) 1457-1459
13. Jenkins T.D., and Friedman L.S. Adenocarcinoma of the esophagogastric junction. Dig Dis 17 (1999) 153-162
14. Morales T.G. Adenocarcinoma of the gastric cardia. Dig Dis 15 (1997) 346-356
15. Barrett N.R. Chronic peptic ulcer of the oesophagus and "oesophagitis.". Br J Surg 38 (1950) 175-182
16. Paull A., Trier J.S., Dalton M.D., et al. The histologic spectrum of Barrett's esophagus. N Engl J Med 295 (1976) 476-480
17. Hayward J. The lower end of the oesophagus. Thorax 16 (1961) 36-41
18. Weinstein W.M., and Ippoliti A.F. The diagnosis of Barrett's esophagus: goblets, goblets, goblets. Gastrointest Endosc 44 (1996) 91-95
19. Cameron A.J., Lomboy C.T., Pera M., et al. Adenocarcinoma of the esophagogastric junction and Barrett's esophagus. Gastroenterology 109 (1995) 1541-1546
20. Lagergren J., Bergstrom R., Lindgren A., et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 340 (1999) 825-831
21. Conio M., Cameron A.J., Romero Y., et al. Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted county, Minnesota. Gut 48 (2001) 304-309
22. Cameron A.J., Zinsmeister A.R., Ballard D.J., et al. Prevalence of columnar-lined (Barrett's) esophagus. comparison of population-based clinical and autopsy findings. Gastroenterology 99 (1990) 918-922
23. Chow W.H., Finkle W.D., McLaughlin J.K., et al. The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA 274 (1995) 474-477
24. Cameron A.J. Epidemiology of columnar-lined esophagus and adenocarcinoma. Gastroenterol Clin North Am 26 (1997) 487-494
25. Drewitz D.J., Sampliner R.E., and Garewal H.S. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 92 (1997) 212-215
26. Kalish R.J., Clancy P.E., Orringer M.B., et al. Clinical, epidemiologic, and morphologic comparison between adenocarcinomas arising in Barrett's esophageal mucosa and in the gastric cardia. Gastroenterology 86 (1984) 461-467
27. Spechler S.J., Zeroogian J.M., Antonioli D.A., et al. Prevalence of metaplasia at the gastro-oesophageal junction. Lancet 344 (1994) 1533-1536
28. Goldstein N.S. Gastric cardia intestinal metaplasia: biopsy follow-up of 85 patients. Mod Pathol 13 (2000) 1072-1079
29. Morales T.G., Camargo E., Bhattacharyya A., et al. Long-term follow-up of intestinal metaplasia of the gastric cardia. Am J Gastroenterol 95 (2000) 1677-1680
30. Clark G.W., Smyrk T.C., Burdiles P., et al. Is Barrett's metaplasia the source of adenocarcinomas of the cardia?. Arch Surg 129 (1994) 609-614
31. Cameron A.J., Souto E.O., and Smyrk T.C. Small adenocarcinomas of the esophagogastric junction: association with intestinal metaplasia and dysplasia. Am J Gastroenterol 97 (2002) 1375-1380
32. Knawy B.A., Morad N.A., Jamal A., et al. Non-neoplastic changes in gastric antrum: are they different in distally located intestinal and diffuse-type gastric adenocarcinoma?. Eur J Cancer Prev 6 (1997) 167-170
33. Wu A.H., Crabtree J.E., Bernstein L., et al. Role of Helicobacter pylori CagA + strains and risk of adenocarcinoma of the stomach and esophagus. Int J Cancer 103 (2003) 815-821
34. Chow W.H., Blaser M.J., Blot W.J., et al. An inverse relation between CagA + strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res 58 (1998) 588-590
35. Ye W., Held M., Lagergren J., et al. Helicobacter pylori infection and gastric atrophy: risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. J Natl Cancer Inst 96 (2004) 388-396
36. Goldblum J.R., Vicari J.J., Falk G.W., et al. Inflammation and intestinal metaplasia of the gastric cardia: the role of gastroesophageal reflux and H. pylori infection. Gastroenterology 114 (1998) 633-639
37. Huang J.Q., Sridhar S., Chen Y., et al. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 114 (1998) 1169-1179
38. Wang H.H., Hsieh C.C., and Antonioli D.A. Rising incidence rate of esophageal adenocarcinoma and use of pharmaceutical agents that relax the lower esophageal sphincter (United States). Cancer Causes Control 5 (1994) 573-578
39. Lagergren J., Bergstrom R., Adami H.O., et al. Association between medications that relax the lower esophageal sphincter and risk for esophageal adenocarcinoma. Ann Intern Med 133 (2000) 165-175
40. Vaughan T.L., Farrow D.C., Hansten P.D., et al. Risk of esophageal and gastric adenocarcinomas in relation to use of calcium channel blockers, asthma drugs, and other medications that promote gastroesophageal reflux. Cancer Epidemiol Biomarkers Prev 7 (1998) 749-756
41. Fu S., Ramanujam K.S., Wong A., et al. Increased expression and cellular localization of inducible nitric oxide synthase and cyclooxygenase 2 in Helicobacter pylori gastritis. Gastroenterology 116 (1999) 1319-1329
42. Farrow D.C., Vaughan T.L., Hansten P.D., et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 7 (1998) 97-102
43. Castellsague X., Munoz N., De Stefani E., et al. Independent and joint effects of tobacco smoking and alcohol drinking on the risk of esophageal cancer in men and women. Int J Cancer 82 (1999) 657-664
44. Wu A.H., Wan P., and Bernstein L. A multiethnic population-based study of smoking, alcohol and body size and risk of adenocarcinomas of the stomach and esophagus (United States). Cancer Causes Control 12 (2001) 721-732
45. Gammon M.D., Schoenberg J.B., Ahsan H., et al. Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 89 (1997) 1277-1284
46. Calle E.E., Rodriguez C., Walker-Thurmond K., et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 348 (2003) 1625-1638
47. Chow W.H., Blot W.J., Vaughan T.L., et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 90 (1998) 150-155
48. Brown L.M., Swanson C.A., Gridley G., et al. Adenocarcinoma of the esophagus: role of obesity and diet. J Natl Cancer Inst 87 (1995) 104-109
49. Lagergren J., Ye W., Bergstrom R., et al. Utility of endoscopic screening for upper gastrointestinal adenocarcinoma. JAMA 284 (2000) 961-962
50. Cheng K.K., Sharp L., McKinney P.A., et al. A case-control study of oesophageal adenocarcinoma in women: a preventable disease. Br J Cancer 83 (2000) 127-132
51. Zhang Z.F., Kurtz R.C., Yu G.P., et al. Adenocarcinomas of the esophagus and gastric cardia: the role of diet. Nutr Cancer 27 (1997) 298-309
52. Terry P., Lagergren J., Ye W., et al. Antioxidants and cancers of the esophagus and gastric cardia. Int J Cancer 87 (2000) 750-754